Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor IX and thrombosis.

L M Aledort

    Scandinavian Journal of Haematology. Supplementum
    |January 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Factor IX concentrates, used for hemophilia B and liver disease, carry a risk of thrombosis. A study found 11% of patients experienced thrombotic events, highlighting the need for safer Factor IX products.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Editorial Foreword.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Chairman's Introduction.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Chairman's Synthesis and closing remarks.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Liver failure and mortality in HIV-positive haemophiliacs: FOURTEEN-YEAR EXPERIENCE AND LITERATURE REVIEW.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    The EPIC study: a lesson to learn.

    Haemophilia : the official journal of the World Federation of Hemophilia·2015

    Area of Science:

    • Hematology
    • Transfusion Medicine

    Background:

    • Factor IX concentrates are available due to fractionation technology.
    • Hepatitis is a known risk, but thrombosis is an emerging concern with Factor IX concentrate use.
    • Existing literature presents conflicting data on the incidence of thrombotic events.

    Purpose of the Study:

    • To investigate the incidence of thrombohemorrhagic phenomena following Factor IX concentrate infusion.
    • To identify potential thrombogenic factors associated with Factor IX concentrates.
    • To emphasize the need for safer Factor IX products.

    Main Methods:

    • A retrospective study analyzing thrombohemorrhagic events in patients receiving Factor IX concentrates.
    • Inclusion criteria: patients with congenital Factor IX deficiency (hemophilia B) or liver disease.

    Related Experiment Videos

  • Data collection focused on documented thrombotic or hemorrhagic episodes post-infusion.

    • Main Results:

    • Twenty episodes of thrombohemorrhagic phenomena were observed in 188 cases.
    • The overall incidence of these events was 11% in the studied population.
    • This incidence rate underscores a significant risk associated with Factor IX concentrate administration.

    Conclusions:

    • Factor IX concentrates are associated with a notable incidence of thrombotic events (11%).
    • Further research is crucial to identify and remove thrombogenic factors from Factor IX products.
    • Ensuring the safety of Factor IX concentrates requires addressing these identified risks.